James Herman - Cumberland Pharmaceuticals VP

CPIX Stock  USD 1.06  0.02  1.85%   

VP

Mr. James L. Herman is Vice President National Accounts and Chief Compliance Officer of Cumberland Pharmaceuticals Inc since 2011.
Age 69
Tenure 13 years
Professional MarksMBA
Address 1600 West End Avenue, Nashville, TN, United States, 37203
Phone615 255 0068
Webhttps://www.cumberlandpharma.com
Herman handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing our corporate compliance efforts. He was with us since 2003 and has 24 years of pharmaceutical industry experience. From 1998 to 2003, he was with Solvay Pharmaceuticals and served as Director of Managed Care and Director of Trade Affairs and Customer Service. From 1990 to 1998, Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.

Cumberland Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.0564) % which means that it has lost $0.0564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3607) %, meaning that it created substantial loss on money invested by shareholders. Cumberland Pharmaceuticals' management efficiency ratios could be used to measure how well Cumberland Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.1 in 2024. Return On Capital Employed is likely to rise to -0.11 in 2024. At this time, Cumberland Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 60.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 27.5 M in 2024.
Cumberland Pharmaceuticals currently holds 18.43 M in liabilities with Debt to Equity (D/E) ratio of 0.5, which is about average as compared to similar companies. Cumberland Pharmaceuticals has a current ratio of 1.76, which is within standard range for the sector. Note, when we think about Cumberland Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 4 records

VP Age

LLB BAKamada
45
MBA MSIronwood Pharmaceuticals
N/A
MPH MDIronwood Pharmaceuticals
N/A
Kipling ThackerLifecore Biomedical
69
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Cumberland Pharmaceu operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. Cumberland Pharmaceuticals (CPIX) is traded on NASDAQ Exchange in USA. It is located in 1600 West End Avenue, Nashville, TN, United States, 37203 and employs 91 people. Cumberland Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Cumberland Pharmaceuticals Leadership Team

Elected by the shareholders, the Cumberland Pharmaceuticals' board of directors comprises two types of representatives: Cumberland Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cumberland. The board's role is to monitor Cumberland Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cumberland Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cumberland Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
John Hamm, Chief Officer
John CMA, VP CFO
Todd Anthony, Vice Development
James Herman, Chief Compliance Officer and VP of National Accounts
Adam Mostafa, Managing Director
Erin Gull, Senior Associate
Jean Marstiller, Senior Secretary
Chris Bitterman, Vice Marketing
A MBA, Chairman, Founder
Cindy Patton, Director Marketing

Cumberland Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cumberland Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cumberland Stock Analysis

When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.